Anub John, MD
Cardiovascular Disease · Kearney, NENPI 1184988933
Payments from drug & device makers
What this record shows
33 manufacturers reported payments, led by Abbott at 33.4% of the total. Reporting peaked in 2019 at $6,230 and has fallen 90.0% since, to $622 in 2025.
Across 194 payments — averaging $54.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Boston Scientific$2K
- Edwards Lifesciences$1K
- Medtronic$1K
- Cardiovascular Systems Inc.$243
- Johnson & Johnson$227
- plus $2K from 27 others
What the payments were for
- Travel & lodging$6,03257%
- Food & beverage$4,48243%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 26 | $3,515 |
| Boston Scientific | 24 | $2,185 |
| Edwards Lifesciences | 11 | $1,245 |
| Medtronic(2 entities) | 17 | $1,201 |
| Cardiovascular Systems Inc. | 20 | $243 |
| Johnson & Johnson | 15 | $227 |
| Novartis | 7 | $219 |
| Chiesi USA, Inc. | 4 | $180 |
| Penumbra, Inc. | 2 | $179 |
| Boehringer Ingelheim | 6 | $142 |
| Pfizer | 6 | $129 |
| E.r. Squibb & Sons, L.L.C. | 7 | $117 |
| Amgen | 6 | $116 |
| Heartflow, Inc. | 5 | $102 |
| Sanofi-aventis U.S. LLC | 6 | $101 |
| Abiomed | 3 | $86 |
| Bridgebio Pharma, Inc. | 2 | $65 |
| Actelion Pharmaceuticals US, Inc. | 3 | $56 |
| Novo Nordisk | 2 | $46 |
| Philips North America LLC | 2 | $39 |
| Siemens Medical Solutions USA, Inc. | 2 | $36 |
| Bayer | 2 | $33 |
| Angiodynamics, Inc. | 2 | $33 |
| Biosense Webster, Inc. | 2 | $33 |
| AstraZeneca | 2 | $28 |
| Teleflex LLC | 1 | $25 |
| Vifor Pharma, Inc. | 2 | $24 |
| W. L. Gore & Associates, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Terumo Medical Corporation | 1 | $16 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VersaCross Access Solution$1,647
- Assurity Pacemaker$1,314
- Cardiovascular- Research only$1,054
- CoreValve Evolut$700
- Omnilink Elite vascular stent system$544
- AMPLATZER Occluders$132
- KENGREAL$126
- ENTRESTO$124
- XARELTO$111
- Penumbra System$106
- COREVALVE EVOLUT R$105
How this compares
$10,514 in reported general payments places this provider in the 80th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 164 | $179,156 |
| FarxigaDapagliflozin Propanediol | 49 | $50,983 |
| JardianceEmpagliflozin | 50 | $36,743 |
| EntrestoSacubitril/Valsartan | 28 | $36,587 |
| XareltoRivaroxaban | 35 | $31,512 |
| Praluent PenAlirocumab | 22 | $23,625 |
| Repatha SureclickEvolocumab | 16 | $8,846 |
| Sildenafil Citrate | 27 | $4,854 |
| Metoprolol Succinate | 289 | $3,736 |
| Atorvastatin Calcium | 327 | $3,188 |
| ClopidogrelClopidogrel Bisulfate | 212 | $2,598 |
| Losartan Potassium | 244 | $1,829 |
| Spironolactone | 280 | $1,767 |
| Carvedilol | 167 | $1,648 |
| Ezetimibe | 92 | $1,622 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $129 | $179,156164 claims |
| AstraZenecaFarxiga | $28 | $50,98349 claims |
| Boehringer IngelheimJardiance | $142 | $36,74350 claims |
| NovartisEntresto | $219 | $36,58728 claims |
| Johnson & JohnsonXarelto | $227 | $31,51235 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Kearney
- Linda FerrerKearney$6K
- Ronald ZoltyOmaha$945K
- Robert PercellLincoln$918K
- Steven KruegerLincoln$388K
- Jeffrey CarstensOmaha$124K
- Keith MillerLincoln$86K
- John HenryOmaha$79K
- Joseph ThibodeauOmaha$75K
- Qais RadaidehOmaha$50K
- Wynn HunterLincoln$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.